Compare · BSX vs MDAI
BSX vs MDAI
Side-by-side comparison of Boston Scientific Corporation (BSX) and Spectral AI Inc. (MDAI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and MDAI operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $67.78B, about 1245.5x MDAI ($54.4M).
- Over the past year, BSX is down 56.2% and MDAI is down 18.8% - MDAI leads by 37.4 points.
- MDAI has been more active in the news (5 items in the past 4 weeks vs 1 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 1 for MDAI).
- Company
- Boston Scientific Corporation
- Spectral AI Inc.
- Price
- $45.59+2.88%
- $1.73-1.71%
- Market cap
- $67.78B
- $54.4M
- 1M return
- -20.21%
- -34.66%
- 1Y return
- -56.22%
- -18.82%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 1
- 5
- Recent ratings
- 25
- 1
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BSX
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest MDAI
- Spectral AI Joins the American Board of Wound Management Foundation in Celebrating Wound Healing Awareness Month
- Spectral AI to Participate in 2026 British Burn Association Annual Conference
- Spectral AI Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits
- Director Dimaio John Michael was granted 17,500 shares, increasing direct ownership by 0.66% to 2,687,847 units (SEC Form 4)
- Spectral AI Announces Voting Results of Annual Meeting of Stockholders
- Director Dimaio John Michael was granted 32,233 shares, increasing direct ownership by 1% to 2,670,347 units (SEC Form 4)
- Spectral AI Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Spectral AI Receives FDA De Novo Clearance for DeepView® System for Burn Indication
- Director Sadagopan Deepak was granted 25,000 shares (SEC Form 4)
- Director Cotton Richard John was granted 14,700 shares, increasing direct ownership by 15% to 111,477 units (SEC Form 4)